본문바로가기
Language
Q
U
I
C
K

Business

SK bioscience’s effort reaches beyond the development and manufacture of its own premium vaccines
and extends to working with domestic and overseas partners to create a healthy future for mankind.

Vaccine Co-Development and Technology Transfer

Leveraging our technical excellence,
we are conducting various joint development and technology transfer projects with global companies
from material supply to product development, clinical trials, and sales.

Joint development

We provide the best solution for faster product development with advanced systems for core competitive R&D
and manufacturing processes and future-oriented investments in joint development.

General Practice
  • 2.5 Years
    • R&D
    • NCS (tox)
  • 1 Year
    • PhaseⅠ/Ⅱ
  • 3 Years
    • Construction
    • CTM* manufacturing
  • 2 Years
    • Phase Ⅲ
  • 1 Year
    • BLA
SK’s cell based influenza vaccine case
  • 2.5 Years
    • R&D
    • NCS(tox)
  • 1 Year
    • PhaseⅠ/Ⅱ
    • Construction
    • CTM* manufacturing
  • 1.5 Years
    • Phase Ⅲ
  • 0.8 Year
    • BLA
6  YEARS

from scratch
to the market

Joint development process

  1. Full or partial funding
  2. Preclinical process development
    Small scale
    manufacturing

    BIO R&D CENTER

  3. Clinical
    Commercial scale
    manufacturing

    L HOUSE

  4. BLA/WHO PQ
  5. Supply
    Post marketing
    commitment

We are working with various global companies and foundations for global healthcare.

Comprehensive collaboration
Comprehensive collaboration PCV image

PCV

R&D, production and marketing
for next generation PCV in 2014

Development & manufacturing
Development & manufacturing TCV image

TCV

Co-development with IVI
(Bill & Melinda Gates Foundation) in 2013

Development & manufacturing
Development & manufacturing NRRV image

NRRV

Modern co-development with PATH
(Bill & Melinda Gates Foundation) in 2017

Development & manufacturing
Development & manufacturing COVID 19(NBP2001) image

COVID 19
(NBP2001)

Development of a recombinant protein vaccine with funding from the Korea Disease Control and Prevention Agency, Ministry of Health and Welfare, and Ministry of Trade, Industry & Energy

Development & manufacturing
Development & manufacturing COVID 19(GBP510) image

COVID 19
(GBP510)

Study of a recombinant protein vaccine candidate (GBP510)—manufactured using a nanoparticle platform—and manufacture of clinical trial materials needed for phase I/II and phase III trials

Development & manufacturing
Development of a general-purpose vaccine for Sarbecovirus under CEPI supported

Sarbecovirus

Development of a general-purpose vaccine for Sarbecovirus under CEPI supported

Development & manufacturing
Co-developement with Bill&Melinda Gates Foundation, IAVI, IPD

Nasal Spray

Co-developement with Bill&Melinda Gates Foundation, IAVI, IPD